- Former CEO David Shaw Named Executive Chairman and Chairman of the Board
-
CLINTON, N.J., Jan. 9 /PRNewswire/ -- Ikaria Holdings, Inc., a fully
integrated critical care biopharmaceutical company, announced today that
Daniel Tasse has been appointed President and Chief Executive Officer. Mr.
Tasse succeeds David Shaw, who has served as Chairman and interim CEO since
the creation of Ikaria Holdings in March 2007 and will now serve as
Executive Chairman and Chairman of the Board.
Mr. Shaw commented, "Daniel is an outstanding fit for the Ikaria
opportunity, and vice versa. He has extensive executive management
experience in 'academy companies' in the pharmaceutical and life sciences
industry, with highly relevant expertise in R&D management, marketing and
sales, and other functions in domestic and international markets. We expect
to benefit strategically and operationally from Daniel's many years of
involvement in both drugs and devices across many therapeutic areas and
healthcare settings, including critical care. His leadership capabilities
and his knowledge of in- hospital markets will be particularly valuable as
Ikaria continues to build an exceptionally strong capability to serve the
needs of critically ill patients."
Daniel Tasse stated, "The formation of Ikaria last year created a
company with the potential to redefine the critical care industry. With
Ikaria's industry-leading INOmax(R) product and a pipeline of unique
therapeutic compounds and numerous business development and R&D
opportunities, we have a very exciting and unique opportunity available to
us. I feel very fortunate to join this team in a leadership position with
the goal of building a legendary company in the years ahead."
Mr. Tasse most recently served as the General Manager of Baxter
International's $2 billion Pharmaceuticals & Technologies business, a
division created by integrating the company's Anesthesia, Critical Care and
BioPharma Solutions Business units. Prior to his tenure at Baxter
International, Mr. Tasse held management positions at GlaxoSmithKline and
Upjohn. He has a B.Sc. in Biochemistry from the University of Montreal.
About Ikaria Holdings, Inc.
Ikaria Holdings, Inc. is a fully integrated biotherapeutics company
focused on the development and commercialization of innovative in-hospital
pharmaceutical products and drug/device combinations for the critically
ill. The company's product, INOmax(R) (nitric oxide) for inhalation, is an
FDA- approved drug for the treatment of hypoxic respiratory failure in term
and near-term newborns. The drug also is approved by regulatory authorities
and used in Canada, Europe, Australia and Latin America. In addition to
marketing and selling its INOmax product, Ikaria is engaged in both Phase
II trials with Covox(R) (carbon monoxide) for inhalation and Phase I trials
with hydrogen sulfide (H2S) for various indications. Ikaria has a staff of
over 300 people and is headquartered in Clinton, NJ, with research
facilities in Seattle, WA and Madison, WI and manufacturing in Port Allen,
LA. For more information on Ikaria, please visit http://www.ikaria.com.
Contacts
Matthew Bennett
Ikaria
908-238-6673
matthew.bennett@ikaria.com
Jason Rando/Catherine Bright
The Ruth Group
646-536-7025/7013
jrando@theruthgroup.com
cbright@theruthgroup.com
SOURCE Ikaria Holdings, Inc.
 back to top
Related links:
http://www.ikaria.com
CONTACT:
Matthew Bennett of Ikaria, +1-908-238-6673,
matthew.bennett@ikaria.com; or Jason Rando, +1-646-536-7025,
jrando@theruthgroup.com, or Catherine Bright, +1-646-536-7013,
cbright@theruthgroup.com, both of The Ruth Group for Ikaria
|
